These data demonstrate the following: that CD8+ T cells from the periphery continue to infiltrate tumors of vehicle-treated mice from day 1 to day 9; that in situ proliferation of tumor-infiltrating CD8+ T cells that survive ATRi QDx3 plus RT treatment is not sufficient to account for the accumulated CD8+ T cell infiltrate by day 9; and that the observed accumulation of CD8+ T cells in TILs of ATRi QDx3 plus RT–treated mice by day 9 requires transit of CD8+ T cells from the periphery. Here, CD8A is linked to neoplasm.